Rheumatology (Oxford). 2022 doi: 10.1093/rheumatology/keac500
Guselkumab (GUS) demonstrates better skin efficacy than most other targeted PsA therapies, including upadacitinib. The objective of this NMA update was to expand the network to include all targeted therapies in PsA on arthritis, skin efficacy and safety, and to include data on GUS patients with an IR to TNFinibs.
In terms of vdH-S both GUS doses used were comparable to most treatments, and generally ranked higher than most. This includes both upadacitinib and risankizumab. The two doses of guselkumab also demonstrate comparable ACR responses to most other agents, including upadacitinib and risankizumab, and rank favourably in the network for SAEs.